DaSH-Global’s Post

With 95% of #entrepreneurs interested in raising capital Logan Plaster, StartUp Health, recently interviewed me to gain my insights and experience around crowdfunding. We have worked with RedCrow, Wefunder, StartEngine, DealMaker as well as PitchBook, KINGSCROWD, and AngelSpan, Inc. for support. Developing #pharmaceuticals for large unmet #healthcare needs is critical. #venturecapital and #familyoffices are an important part of the long game and #crowdfunding is a CRITICAL part of the short game. Sen-Jam Pharmaceutical is focused on developing #therapeutics for precision #medicine to change the course of #inflammation.

🚀 Only 10 days left of our crowdfunding campaign — Join the healthcare revolution 🚀 We’re excited to announce that eNavvi has already raised $66,874, and we're growing rapidly! With 50% month-over-month growth, we've secured partnerships with 35,000+ pharmacy locations nationwide, including CVS, Walgreens, and Walmart. 💊 We’re also expanding our medication list to over 10,000 options, including top-prescribed drugs like Ozempic and Zepbound. Plus, our eNavvi app launches this October, making prescribing even easier for doctors on the go! But there are only 10 days left to be part of this exciting journey! Our crowdfunding campaign ends on September 30th, so now’s the time to invest in the future of healthcare. Become more than a user—become an investor in a company that's transforming prescribing and reshaping the healthcare landscape. 🔗 Learn more and invest before it’s too late: https://hubs.la/Q02QDKSm0 #HealthcareInnovation #Crowdfunding #DigitalHealth #Pharmacy #eNavvi #PrescriptionSavings #AffordableHealthcare #MedicalCare #Physicians #Pharmacists #Medicine #Education #Startup #Medtech

Series A activity: Week of December 11, 2023. Highlight is certainly Mistral AI's $400M+ round which was categorized as an A. #startupfunding #venturefunding #vcfunding #vc #startups #seriesa #seriesafunding

Last chance to join Pirche's mission to revolutionize organ transplants  🔬 PIRCHE’s groundbreaking crowdfunding campaign on Invesdor DACH is closing soon—𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟰𝘁𝗵 is your last chance to get involved! ⏳ 💔 𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄? 50% of transplanted organs fail within 5–10 years, putting countless patients at risk. But Pirche is changing that reality. Their 𝗔𝗜-𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 matches donors and recipients with mind-blowing precision—in just three seconds! ⚡ 🔍 This innovation allows transplant specialists to predict the course of an organ transplant 𝘂𝗽 𝘁𝗼 𝟮𝟬 𝘆𝗲𝗮𝗿𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲, ensuring the best possible matches and transforming patient outcomes. Better-matched organs mean shorter waiting lists and a new lease on life for countless patients. 🌱 Pirche’s mission doesn’t end with kidneys—they’re expanding this life-saving technology to other organs. And 𝘁𝗵𝗲𝘆 𝗻𝗲𝗲𝗱 𝘆𝗼𝘂𝗿 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 to make it happen 🙌 💡 𝗝𝗼𝗶𝗻 𝗵𝘂𝗻𝗱𝗿𝗲𝗱𝘀 𝗼𝗳 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 who have already taken the leap to support Pirche’s vision. Become a co-owner in this health tech revolution and make a 𝗿𝗲𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁. 👉 Visit the campaign page via the link in the comments. 🚀 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝘁! The campaign ends on 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟰𝘁𝗵—your chance to be part of something truly transformative. #crowdfunding #healthtech #organtransplant #pirche #invesdor #lastchance #medicalinnovation

Sound Bioventures is a venture capital fund investing in about-to-be clinical and clinical stage private companies in Europe and the USA developing novel medicines that address unmet medical needs. We focus on specialty therapeutic areas and diseases with significant clinical unmet need. My fellow founding partners, Johan Kördel and Bibhash Mukhopadhyay, and I started Sound Bioventures about three years ago. We raised $125m for our first fund out of which we are now investing. We first learned about Artax Biopharma (three years ago) during their Series B round. The management team pitched us on a new approach to autoimmune, one in which T cell response modulation via Nck seemed to make a lot of sense. They presented compelling in vitro and in vivo data to support the thesis, and they were looking to raise money for clinical trials with a lead asset. We then dug in and concluded that this was a very promising approach; if successful, it could create a true paradigm shift in how autoimmune diseases are treated. At Sound Bioventures, we wish to support ideas which can have the most impact for patients, so the Artax project fits very well. Execution by the new management team this year has been excellent. The Phase 2a patient trial in psoriasis is now fully recruited, on track for a data readout before year end. They’ve been doing a good job of getting the word out about Nck modulation and the AX-158 patient trial data coming in. When they knocked on the door to do a convertible financing round, we were all in. Now we are waiting for the data. It will be very interesting to see where the science takes us on this journey: does the patient readout confirm what the in vitro assays and animal models predicted? We have made the bet and can’t wait to see the data! - Casper Breum, managing partner at Sound Bioventures

Early results from their Golden Retriever model, which mirrors Duchenne muscular dystrophy in humans, show promising reductions in creatinine kinase markers, indicating potential efficacy. Read more 👉 https://lttr.ai/AUkf7 #Crowdfunding #Equitycrowdfunding #Marketing #SocialMedia #Community #ImprovePatientsQuality #ShowPromisingReductions #crowdfunding #equitycrowdfunding

#London-based Evaro secures $1.5Million in seed #funding. Cornerstone VC and Exceptional Ventures led the round, including participation from the University of East Anglia and Syndicate Room, Catalisi’s investing arm. With the money, the business will expand into the B2B #sector by developing a plug-and-play solution that would enable #consumer brands to give their clients managed #prescription services. With the funds, Evaro will be able to provide 2,000 #treatments instead of just 200, covering 70% of the minor health conditions that NHS doctors generally #treat. The organization also hopes to obtain a treatment #Quality Commission (CQC) license, which would allow for more thorough patient treatment, including the beginning of therapy and #diagnosis. With only one line of code, they allow brands to easily #incorporate prescription medicine services into their product offers. For forward-thinking companies wishing to get into the #digital health market, Evaro offers a turnkey solution. Evaro Cornerstone VC Exceptional Ventures SyndicateRoom Thuria Wenbar Oskar Wendowski PhD To share your startup story write us on - contact@startuprise.co.uk #evaro #funding #eustartup

Our crowdfunding campaign is closing in just 2 days’ time, on Wednesday 3rd July. We’ve raised an incredible £590K from over 450 investors but there’s still time to join us (just!) for as little as £12.36. PinPoint comprises a world-class data science team with business leaders who bring decades of experience in delivering innovation in the healthcare system. It is a really busy and buoyant time for us, with 14,300+ PinPoint tests carried out to date as part of an observational NHS service evaluation, and £1 million of Innovate UK funding awarded to support the next stages of development. A key reason for inviting investment at this point is to support commercialisation, which we’re very close to. Alongside continuing our NHS partnerships for our business growth in the UK, we’re also preparing to do the groundwork for roll-out overseas in the next 2-3 years. We aim to complete all the necessary EU and FDA preparations for this whilst building international partnerships. As every one of us will be affected by cancer at some point in our lives, the impact PinPoint can have is huge. By becoming a shareholder, you’ll be joining what is both an impactful mission and strong investment opportunity. If you’re yet to secure your shares in PinPoint please click through to Crowdcube below ASAP. To everyone who has invested - a sincere thank you from us. We look forward to welcoming you to PinPoint! https://lnkd.in/eaUx6g3b #pinpointest #crowdfunding #EIS #investment #raising #NHS #cancer #AI #machinelearning #medtech Don’t invest unless you’re prepared to lose all the money you invest

🚀 Momentum on the Rise: Cytonics Makes a Mark on StartEngine 🌟 invest.cytonics.com We're thrilled to share that Cytonics has been featured in StartEngine's "Most Momentum" category, signaling a strong surge in interest from investors who believe in our mission to revolutionize #osteoarthritis care. 🩺 With over $404K raised and 175 dedicated investors joining our cause, we're not just building momentum; we're accelerating towards a future where osteoarthritis can be effectively targeted and treated. Our groundbreaking drug, "CYT-108," has shown promising results in preclinical studies, taking aim at the very root of osteoarthritis damage. To our community of investors and supporters: Your trust fuels our journey. Together, we're not just part of a funding round; we're part of a healthcare revolution. 💡 Here's to reaching new milestones, embracing innovation, and improving lives. Thank you for being an integral part of our story. 💼Join the movement. Invest in a future free from osteoarthritis pain: invest.cytonics.com #biotechnology #investing #crowdfunding

🚀 Momentum on the Rise: Cytonics Makes a Mark on StartEngine 🌟 invest.cytonics.com We're thrilled to share that Cytonics has been featured in StartEngine's "Most Momentum" category, signaling a strong surge in interest from investors who believe in our mission to revolutionize #osteoarthritis care. 🩺 With over $404K raised and 175 dedicated investors joining our cause, we're not just building momentum; we're accelerating towards a future where osteoarthritis can be effectively targeted and treated. Our groundbreaking drug, "CYT-108," has shown promising results in preclinical studies, taking aim at the very root of osteoarthritis damage. To our community of investors and supporters: Your trust fuels our journey. Together, we're not just part of a funding round; we're part of a healthcare revolution. 💡 Here's to reaching new milestones, embracing innovation, and improving lives. Thank you for being an integral part of our story. 💼Join the movement. Invest in a future free from osteoarthritis pain: invest.cytonics.com #biotechnology #investing #crowdfunding